- Arbutus Biopharma Corporation is an industry-leading early clinical-stage biopharmaceutical company focused on developing a cure for patients with chronic hepatitis B virus.
- Arbutus's early-stage pipeline is designed for using a combination of their four drug-candidates to treat the main drivers of HBV, including candidates that address HBV persistence, immune reactivation, and cccDNA presence.
- The company's cash at 9m 2020 reached $118M after +$67M in common stock issuances over the same period, equating to approximately 1.5 years of funding on top of $4.5M in collaboration/licensing revenues.
- Arbutus has two key catalysts upcoming in 1Q 2021: the announcement of AB-836 CTA/IND's study completion and AB-729's more definitive multi-dose additive data announcement.
- In summary, the author projects Arbutus Biopharma Corporation as a "buy" at a 2-3 year price target of $10 (+147% upside).
For further details see:
Arbutus: A Promising Pure-Play On The $2.13 Billion Global Hepatitis B Market